{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:40:13Z","timestamp":1787236813386,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972547"],"award-info":[{"award-number":["81972547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["52473279"],"award-info":[{"award-number":["52473279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04662-1","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T03:46:33Z","timestamp":1781408793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A biomimetic nanointegrator synergizing \u201cdual-throttle\u201d immune checkpoint blockade and enhanced DAMPs-mediated immune activation for potent anti-tumor T\u2011cell immunity"],"prefix":"10.1186","volume":"24","author":[{"given":"Han-Zhe","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Jun","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Feng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"key":"4662_CR1","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.cell.2023.02.039","volume":"186","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Schwab RD, Brookens SK, Posey AD. Jr. Advances in cancer immunotherapies. Cell. 2023;186:1814.","journal-title":"Cell"},{"key":"4662_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, Sethi G, Zhao P, Liu S. Advances in cancer immunotherapy: Historical perspectives, current developments, and future directions. Mol Cancer. 2025;24:136.","journal-title":"Mol Cancer"},{"key":"4662_CR3","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41467-021-21497-6","volume":"12","author":"C Jiang","year":"2021","unstructured":"Jiang C, Chen K, Liu A, Huang H, Fan Y, Zhao D, Ye Q, Zhang H, Xu C, Shen S, et al. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy. Nat Commun. 2021;12:1359.","journal-title":"Nat Commun"},{"key":"4662_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002\u201314.","journal-title":"Lancet"},{"key":"4662_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","volume":"19","author":"FG Dall\u2019Olio","year":"2022","unstructured":"Dall\u2019Olio FG, Marabelle A, Caramella C, Garcia C, Aldea M, Chaput N, Robert C, Besse B. Tumour burden and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2022;19:75\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"4662_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","volume":"9","author":"SJ Wang","year":"2023","unstructured":"Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer. 2023;9:543\u201353.","journal-title":"Trends Cancer"},{"key":"4662_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.","journal-title":"Nat Rev Dis Primers"},{"key":"4662_CR8","doi-asserted-by":"publisher","first-page":"eabo5987","DOI":"10.1126\/scitranslmed.abo5987","volume":"14","author":"Z Gu","year":"2022","unstructured":"Gu Z, Yao Y, Yang G, Zhu G, Tian Z, Wang R, Wu Q, Wang Y, Wu Y, Chen L, et al. Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy. Sci Transl Med. 2022;14:eabo5987.","journal-title":"Sci Transl Med"},{"key":"4662_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-020-00340-2","volume":"5","author":"Y Kang","year":"2020","unstructured":"Kang Y, He W, Ren C, Qiao J, Guo Q, Hu J, Xu H, Jiang X, Wang L. Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. Signal Transduct Target Ther. 2020;5:245.","journal-title":"Signal Transduct Target Ther"},{"key":"4662_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-023-01846-3","volume":"22","author":"N Khera","year":"2023","unstructured":"Khera N, Rajkumar AS, Abdulkader M, Alkurdi K, Liu Z, Ma H, Waseem A, Teh MT. Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells. Mol Cancer. 2023;22:146.","journal-title":"Mol Cancer"},{"key":"4662_CR11","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1097\/JS9.0000000000001306","volume":"110","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhong N, Cao L, Liu B, Bu L. Surgical margins in head and neck squamous cell carcinoma: A narrative review. Int J Surg. 2024;110:3680\u2013700.","journal-title":"Int J Surg"},{"key":"4662_CR12","doi-asserted-by":"publisher","first-page":"e2307679","DOI":"10.1002\/adma.202307679","volume":"36","author":"T He","year":"2024","unstructured":"He T, Wen J, Wang W, Hu Z, Ling C, Zhao Z, Cheng Y, Chang YC, Xu M, Jin Z, et al. Peptide-driven proton sponge nano-assembly for imaging and triggering lysosome-regulated immunogenic cancer cell death. Adv Mater. 2024;36:e2307679.","journal-title":"Adv Mater"},{"key":"4662_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2021.07.038","volume":"337","author":"A Banstola","year":"2021","unstructured":"Banstola A, Poudel K, Kim JO, Jeong JH, Yook S. Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death. J Control Release. 2021;337:505\u201320.","journal-title":"J Control Release"},{"key":"4662_CR14","doi-asserted-by":"publisher","first-page":"18818","DOI":"10.1021\/acsnano.3c03274","volume":"17","author":"G Chen","year":"2023","unstructured":"Chen G, Li X, Li R, Wu K, Lei Z, Dai R, Roche K, Wang AZ, Min Y. Chemotherapy-induced neoantigen nanovaccines enhance checkpoint blockade cancer immunotherapy. ACS Nano. 2023;17:18818\u201331.","journal-title":"ACS Nano"},{"key":"4662_CR15","first-page":"24506","volume":"145","author":"Y Li","year":"2023","unstructured":"Li Y, Liu X, Yu L, Huang X, Wang X, Han D, Yang Y, Liu Z. Covalent lytac enabled by DNA aptamers for immune checkpoint degradation therapy. J Am Chem Soc. 2023;145:24506\u201321.","journal-title":"J Am Chem Soc"},{"key":"4662_CR16","doi-asserted-by":"publisher","first-page":"e2309204","DOI":"10.1002\/advs.202309204","volume":"11","author":"LP Zhao","year":"2024","unstructured":"Zhao LP, Zheng RR, Rao XN, Huang CY, Zhou HY, Yu XY, Jiang XY, Li SY. Chemotherapy-enabled colorectal cancer immunotherapy of self-delivery nano-protacs by inhibiting tumor glycolysis and avoiding adaptive immune resistance. Adv Sci. 2024;11:e2309204.","journal-title":"Adv Sci"},{"key":"4662_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2019.09.021","volume":"313","author":"X Wei","year":"2019","unstructured":"Wei X, Liu L, Li X, Wang Y, Guo X, Zhao J, Zhou S. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy. J Control Release. 2019;313:42\u201353.","journal-title":"J Control Release"},{"key":"4662_CR18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1161\/CIRCRESAHA.120.317626","volume":"127","author":"PW Burridge","year":"2020","unstructured":"Burridge PW, Thorp EB. Doxorubicin-induced ascension of resident cardiac macrophages. Circ Res. 2020;127:628\u201330.","journal-title":"Circ Res"},{"key":"4662_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","volume":"12","author":"E Christidi","year":"2021","unstructured":"Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12:339.","journal-title":"Cell Death Dis"},{"key":"4662_CR20","doi-asserted-by":"publisher","first-page":"20230037","DOI":"10.1002\/EXP.20230037","volume":"4","author":"Z Cao","year":"2024","unstructured":"Cao Z, Liu J, Yang X. Deformable nanocarriers for enhanced drug delivery and cancer therapy. Exploration. 2024;4:20230037.","journal-title":"Exploration"},{"key":"4662_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41419-019-1819-3","volume":"10","author":"K Tatsuno","year":"2019","unstructured":"Tatsuno K, Yamazaki T, Hanlon D, Han P, Robinson E, Sobolev O, Yurter A, RiveraMolina F, Arshad N, Edelson RL, et al. Extracorporeal photochemotherapy induces bona fide immunogenic cell death. Cell Death Dis. 2019;10:578.","journal-title":"Cell Death Dis"},{"key":"4662_CR22","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Science. 2017;355:1428\u201333.","journal-title":"Science"},{"key":"4662_CR23","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.1038\/s41467-023-43914-8","volume":"14","author":"R Bhatta","year":"2023","unstructured":"Bhatta R, Han J, Liu Y, Bo Y, Lee D, Zhou J, Wang Y, Nelson ER, Chen Q, Zhang XS, et al. Metabolic tagging of extracellular vesicles and development of enhanced extracellular vesicle based cancer vaccines. Nat Commun. 2023;14:8047.","journal-title":"Nat Commun"},{"key":"4662_CR24","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1016\/j.apsb.2021.03.012","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Li X, Zhang W, Yu L, Wang Y, Deng Z, Liu M, Mo S, Wang R, Zhao J, et al. Trends in the biological functions and medical applications of extracellular vesicles and analogues. Acta Pharm Sin B. 2021;11:2114\u201335.","journal-title":"Acta Pharm Sin B"},{"key":"4662_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jconrel.2024.10.069","volume":"376","author":"T Li","year":"2024","unstructured":"Li T, Li B, Lin L, Chen G, Wang X, Chen Y, Huang W, Cai M, Shuai X, Zhu K. Anti-CTLA-4 antibody self-presented dendritic cell nanovesicles boost the immunotherapy of hepatocellular carcinoma after microwave ablation. J Control Release. 2024;376:913\u201329.","journal-title":"J Control Release"},{"key":"4662_CR26","doi-asserted-by":"publisher","first-page":"e2106265","DOI":"10.1002\/adma.202106265","volume":"34","author":"F Xu","year":"2022","unstructured":"Xu F, Fei Z, Dai H, Xu J, Fan Q, Shen S, Zhang Y, Ma Q, Chu J, Peng F, et al. Mesenchymal stem cell-derived extracellular vesicles with high PD-L1 expression for autoimmune diseases treatment. Adv Mater. 2022;34:e2106265.","journal-title":"Adv Mater"},{"key":"4662_CR27","doi-asserted-by":"publisher","first-page":"1707112","DOI":"10.1002\/adma.201707112","volume":"30","author":"X Zhang","year":"2018","unstructured":"Zhang X, Wang C, Wang J, Hu Q, Langworthy B, Ye Y, Sun W, Lin J, Wang T, Fine J, et al. PD-1 blockade cellular vesicles for cancer immunotherapy. Adv Mater. 2018;30:1707112.","journal-title":"Adv Mater"},{"key":"4662_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12951-022-01266-3","volume":"20","author":"H Chen","year":"2022","unstructured":"Chen H, Zhang P, Shi Y, Liu C, Zhou Q, Zeng Y, Cheng H, Dai Q, Gao X, Wang X, et al. Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy. J Nanobiotechnol. 2022;20:61.","journal-title":"J Nanobiotechnol"},{"key":"4662_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1021\/acsnano.9b07212","volume":"14","author":"W Yang","year":"2020","unstructured":"Yang W, Zhang F, Deng H, Lin L, Wang S, Kang F, Yu G, Lau J, Tian R, Zhang M, et al. Smart nanovesicle-mediated immunogenic cell death through tumor microenvironment modulation for effective photodynamic immunotherapy. ACS Nano. 2020;14:620\u201331.","journal-title":"ACS Nano"},{"key":"4662_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.apsb.2023.08.033","volume":"14","author":"H Liu","year":"2024","unstructured":"Liu H, Luo G, Shang Z. Plant-derived nanovesicles as an emerging platform for cancer therapy. Acta Pharm Sin B. 2024;14:133\u201354.","journal-title":"Acta Pharm Sin B"},{"key":"4662_CR31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41565-025-01931-2","volume":"20","author":"Z Li","year":"2025","unstructured":"Li Z, Wang Y, Mo F, Wolter T, Hong R, Barrett A, Richmond N, Liu F, Chen Y, Yang X, et al. Engineering pyroptotic vesicles as personalized cancer vaccines. Nat Nanotechnol. 2025;20:1108\u201318.","journal-title":"Nat Nanotechnol"},{"key":"4662_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-023-01382-y","volume":"8","author":"M Zhang","year":"2023","unstructured":"Zhang M, Hu S, Liu L, Dang P, Liu Y, Sun Z, Qiao B, Wang C. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct Target Ther. 2023;8:124.","journal-title":"Signal Transduct Target Ther"},{"key":"4662_CR33","doi-asserted-by":"publisher","first-page":"2302131","DOI":"10.1002\/advs.202302131","volume":"10","author":"Q Cheng","year":"2023","unstructured":"Cheng Q, Kang Y, Yao B, Dong J, Zhu Y, He Y, Ji X. Genetically engineered-cell-membrane nanovesicles for cancer immunotherapy. Adv Sci. 2023;10:2302131.","journal-title":"Adv Sci"},{"key":"4662_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.actbio.2023.03.002","volume":"161","author":"B Li","year":"2023","unstructured":"Li B, Yang T, Liu J, Yu X, Li X, Qin F, Zheng J, Liang J, Zeng Y, Zhou Z, et al. Genetically engineered PD-1 displaying nanovesicles for synergistic checkpoint blockades and chemo-metabolic therapy against non-small cell lung cancer. Acta Biomater. 2023;161:184\u2013200.","journal-title":"Acta Biomater"},{"key":"4662_CR35","doi-asserted-by":"publisher","first-page":"158469","DOI":"10.1016\/j.cej.2024.158469","volume":"503","author":"H Liu","year":"2025","unstructured":"Liu H, Liu Z, Liang W, Tang H, Yu L, Wang T, Liu L, Chen Q, Wang J-W, Zhang X-Z, et al. Tea leaf-derived nanovesicles for ferric-supply-amplified ICD and macrophage reprogramming to boost immunotherapy against head and neck squamous carcinoma. Chem Eng J. 2025;503:158469.","journal-title":"Chem Eng J"},{"key":"4662_CR36","doi-asserted-by":"publisher","first-page":"9963","DOI":"10.1021\/acs.nanolett.3c02983","volume":"23","author":"Z Liu","year":"2023","unstructured":"Liu Z, Ji P, Liu H, Yu L, Zhang S, Liu P, Zhang X, Luo G, Shang Z. Fniii14 peptide-enriched membrane nanocarrier to disrupt stromal barriers through reversing CAFs for augmenting drug penetration in tumors. Nano Lett. 2023;23:9963\u201371.","journal-title":"Nano Lett"},{"key":"4662_CR37","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.7150\/thno.106999","volume":"15","author":"S Wu","year":"2025","unstructured":"Wu S, Wang Q, Du J, Meng Q, Li Y, Miao Y, Miao Q, Wu J. A p-n heterojunction sonosensitizer for improved sono-immunotherapy via induction of multimodal cell death mechanisms. Theranostics. 2025;15:2737\u201356.","journal-title":"Theranostics"},{"key":"4662_CR38","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.7150\/thno.102284","volume":"15","author":"Y Wu","year":"2025","unstructured":"Wu Y, Zhao Z, Ma M, Zhang W, Liu W, Liang X, Zhao T, Luo Y, Wang Y, Li M, et al. Ultrasound-activated erythrocyte membrane-camouflaged Pt(II) layered double hydroxide enhances PD-1 inhibitor efficacy in triple-negative breast cancer through cGAS-STING pathway-mediated immunogenic cell death. Theranostics. 2025;15:1456\u201377.","journal-title":"Theranostics"},{"key":"4662_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s43018-020-0038-2","volume":"1","author":"R Thibaut","year":"2020","unstructured":"Thibaut R, Bost P, Milo I, Cazaux M, Lema\u00eetre F, Garcia Z, Amit I, Breart B, Cornuot C, Schwikowski B, et al. Bystander IFN-\u03b3 activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat Cancer. 2020;1:302\u201314.","journal-title":"Nat Cancer"},{"key":"4662_CR40","doi-asserted-by":"publisher","first-page":"e20190347","DOI":"10.1084\/jem.20190347","volume":"217","author":"S Kang","year":"2020","unstructured":"Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020;217:e20190347.","journal-title":"J Exp Med"},{"key":"4662_CR41","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"BB Aggarwal","year":"2012","unstructured":"Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651\u201365.","journal-title":"Blood"},{"key":"4662_CR42","doi-asserted-by":"crossref","unstructured":"Kim DY, Pyo A, Yun M, Thangam R, You SH, Zhang Y, Jung Y r, Nguyen DH, Venu A, Kim HS et al. Imaging calreticulin for early detection of immunogenic cell death during anticancer treatment. J Nucl Med. 2021;62:956\u2013960.","DOI":"10.2967\/jnumed.120.245290"},{"key":"4662_CR43","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat Immunol. 2019;20:1231\u201343.","journal-title":"Nat Immunol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04662-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04662-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:07:25Z","timestamp":1787234845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04662-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4662"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04662-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,14]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures were conducted in Animal Experiment Laboratory of School & Hospital of Stomatology of Wuhan University, in accordance with the GB\/T 35892\u2009\u2212\u20092018 Laboratory animal - Guideline for ethical review of animal welfare and approved by the Animal Ethics Committee of School & Hospital of Stomatology of Wuhan University (IACUC NO: S07923040C).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"785"}}